<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568175</url>
  </required_header>
  <id_info>
    <org_study_id>JR-141-301</org_study_id>
    <nct_id>NCT03568175</nct_id>
  </id_info>
  <brief_title>A Study of JR-141 in Patients With Mucopolysaccharidosis II</brief_title>
  <official_title>A Phase II/III Study of JR-141 in Patients With Mucopolysaccharidosis II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JCR Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JCR Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and
      safety of study drug for the treatment of the MPS II.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Heparan Sulfate Levels.</measure>
    <time_frame>Baseline, 24-26 weeks, 50-52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Dermatan Sulfate Levels.</measure>
    <time_frame>Baseline, 24-26 weeks, 50-52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Heparan Sulfate Levels.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Dermatan Sulfate Levels.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Liver Volumes.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spleen Volumes.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cardiac Function.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 6-minute Walk Test Distance.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
    <description>Item 9 will be administrated only in patients judged by the investigator or subinvestigator to be possible to perform the 6-minutes walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Joint Range of Motion.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid.</measure>
    <time_frame>Baseline to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Testing (Kyoto Scale of Psychological Development 2001)</measure>
    <time_frame>25, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Adaptive Behavioral Testing ( Vineland Adaptive Behavior Scales Second Edition. )</measure>
    <time_frame>25, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentration in Cerebrospinal Fluid.</measure>
    <time_frame>25, 52*weeks</time_frame>
    <description>*Drug concentration in Cerebrospinal Fluid at 52 Weeks is applicable only for subjects to be enrolled in extension study .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>JR-141 2.0 mg/kg/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JR-141</intervention_name>
    <description>IV infusion, 2.0 mg/kg/week</description>
    <arm_group_label>JR-141 2.0 mg/kg/week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable of providing written consent by himself (not mandatory for those aged under 20
             years at the time of informed consent process, or those who is impossible to obtain
             consent from the patient himself due to intellectual disabilities associated with MPS
             II.)

          2. In the case of a patient who is under the age of 20 years or from whom it is not
             possible to obtain consent due to intellectual disabilities associated with MPS II, he
             may be included if written consent can be provided by legal representative (however,
             written consent should be obtained from the patient himself too, whenever possible)

          3. Males with confirmed diagnosis of MPS II, based on deficient activity of
             iduronate-2-sulfatase (IDS) in leucocytes, plasma or fibroblasts and/or pathogenic
             mutations identified in the IDS gene, etc.

          4. Na√Øve patients or patients who are receiving stable enzyme replacement therapy with
             Elaprase for more than 8 weeks before the observational period starts.

        Exclusion Criteria:

          1. Previous engrafted HSCT, excluding those who need enzyme replacement therapy even
             after HSCT.

          2. Judged by the investigator or subinvestigator as being unable to undergo lumbar
             puncture, including those who have difficulties in taking position for lumbar puncture
             due to joint contracture or those who are likely experience difficulty breathing
             during the lumbar puncture process.

          3. Judged by the investigator or subinvestigator to be ineligible to participate in the
             study due to a history of serious drug allergy or sensitivity.

          4. Patients who have received other investigational product within 4 months before
             enrollment in the study.

          5. Otherwise judged by the investigator or subinvestigator to be ineligible to
             participate in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fukui Clinical site</name>
      <address>
        <city>Fukui</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical site 2</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical site</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Clinical site</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Clinical site</name>
      <address>
        <city>Hokkaido</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Clinical site</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Clinical site</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Clinical site 2</name>
      <address>
        <city>Okayama</city>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okinawa Clinical site</name>
      <address>
        <city>Okinawa</city>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site 3</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site 2</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical site</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Clinical site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Clinical site 2</name>
      <address>
        <city>Shizuoka</city>
        <zip>426-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Clinical site</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical site</name>
      <address>
        <city>Tokyo</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori Clinical site</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

